Ribomic Inc. | Income Statement

Fiscal year is April-March. All values JPY Thousands.
2014
2015
2016
2017
2018
2019
Sales/Revenue
151,220.00
479,871.00
121,911.00
93,773.00
64,727.00
7,949
Cost of Goods Sold (COGS) incl. D&A
12,696.00
-
-
-
-
-
Gross Income
138,524.00
-
-
-
-
-
SG&A Expense
552,999.00
454,899.00
639,704.00
842,770.00
937,760.00
909,072
EBIT
414,475.00
6,180.00
532,389.00
785,903.00
899,894.00
928,626
Unusual Expense
-
10,328.00
-
-
-
-
Non Operating Income/Expense
203,437.00
15,199.00
208,871.00
139,520.00
147,661.00
92,390
Pretax Income
210,881.00
11,646.00
322,103.00
645,393.00
751,838.00
835,414
Income Tax
950.00
1,348.00
1,210.00
1,210.00
1,210.00
1,210
Consolidated Net Income
211,831.00
10,298.00
323,313.00
646,603.00
753,048.00
836,624
Net Income
211,831.00
10,298.00
323,313.00
646,603.00
753,048.00
836,624
Net Income After Extraordinaries
211,831.00
10,298.00
323,313.00
646,603.00
753,048.00
836,624
Net Income Available to Common
211,831.00
10,298.00
323,313.00
646,603.00
753,048.00
836,624
EPS (Basic)
20.24
0.88
24.92
48.83
55.61
58.22
Basic Shares Outstanding
10,468.30
11,721.80
12,971.70
13,241.00
13,542.20
14,370.50
EPS (Diluted)
20.24
0.78
24.92
48.83
55.61
58.22
Diluted Shares Outstanding
10,468.30
13,255.70
12,971.70
13,241.00
13,542.20
14,370.50
EBITDA
401,779.00
24,972.00
517,793.00
748,997.00
873,033.00
901,123
Non-Operating Interest Income
157.00
595.00
1,415.00
988.00
394.00
823

About Ribomic

View Profile
Address
Shirokanedai Usui Building, 6/F
Tokyo Tokyo 108
Japan
Employees -
Website http://www.ribomic.com/
Updated 07/08/2019
RIBOMIC, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for use in therapeutic fields. It utilizes RiboART system, a platform technology essentially applicable to any target proteins, and not limited to disease. The company was founded by Yoshikazu Nakamura on August 1, 2003 and is headquartered in Tokyo, Japan.